:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Authors:	Ying Lu, Hao Dai, Huilin Tang, William T. Donahoo, Thomas J. George, Ramon C. Sun, Sizun Jiang, Aik Choon Tan, Yi Guo, Jonathan D. Licht, John M. Allen, Kelvin P. Lee, Jingchuan Guo, Jiang Bian
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Obesity
Online Access:	https://onlinelibrary.wiley.com/doi/10.1002/oby.24366
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

GLP‐1 Receptor Agonists and Substance Use Disorders in Older Adults With Type 2 Diabetes: A Target Trial Emulation
by: Hao Dai, et al.
Published: (2025)

Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials
by: Ying Lu, et al.
Published: (2024)

Glucagon‐Like Peptide‐1 Receptor Agonists: Considerations for Treating Preconception Obesity
by: Lauren T. Berube, et al.
Published: (2026)

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults
by: Jie‐Syuan Wu, et al.
Published: (2026)

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Obstructive Sleep Apnea
by: Bei‐Bei Qian, et al.
Published: (2025)

Association of Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
by: Hezekiah C. T. Au, et al.
Published: (2026)

Continuous glucose monitoring and all‐cause mortality in insulin‐using population with diabetes and cognitive impairment
by: Pareeta Kotecha, et al.
Published: (2024)

Obesity and Female Reproductive Health; Is There a Role for Glucagon‐Like Peptide‐1 Receptor Agonists?
by: Rachel Roberts, et al.
Published: (2025)

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review
by: Timothy H. Chan, et al.
Published: (2026)

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study
by: Arvid Engström, et al.
Published: (2026)

How Bioethics and Reproductive Justice Ought to Inform Glucagon‐Like Peptide‐1 Receptor Agonists, Research, and Pregnancy
by: Nishita Pondugula, et al.
Published: (2025)

Weight Changes From Glucagon‐Like Peptide‐1 Receptor Agonist Use and Discontinuation: A Retrospective Cohort Study
by: G. Caleb Alexander, et al.
Published: (2025)

Effects of Glucagon‐Like Peptide‐1 Receptor Agonists (Mono and Combination Therapy) on Energy Expenditure: A Scoping Review
by: Flavio T. Vieira, et al.
Published: (2026)

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population‐Based Cohort Study
by: Huilin Tang, et al.
Published: (2024)

Association of Glucagon‐Like Peptide Agonist Therapy With Dietary Patterns in a Cross‐Sectional Cohort
by: Eric J. Brandt, et al.
Published: (2025)

Association of Glucagon‐Like Peptide‐1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
by: Shumeng Han, et al.
Published: (2026)

Association of GLP ‐1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation
by: Tahmid Hussain, et al.
Published: (2026)

Adherence and Persistence Among Individuals Living With Type 2 Diabetes and Using a Free Combination of Basal Insulin and an Injectable Glucagon‐Like Peptide‐1 Receptor Agonist Versus a Fixed‐Ratio Combination Therapy: A Japanese Database Study
by: Takeshi Miyatsuka, et al.
Published: (2026)

Sodium‐glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real‐world patients with type 2 diabetes
by: Jingchuan Guo, et al.
Published: (2024)

Assessing the benefit–risk profile of newer glucose‐lowering drugs: A systematic review and network meta‐analysis of randomized outcome trials
by: Huilin Tang, et al.
Published: (2024)

Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )
by: David Stone, et al.
Published: (2026)

Type 2 Diabetes and the Glucagon Renaissance: Restoring Bihormonal Equilibrium
by: Abdelilah Arredouani
Published: (2026)

Efficacy and Safety of GLP ‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA
by: Binayak Sinha, et al.
Published: (2025)

Health Inequities in Older Adults With Type 1 Diabetes: A Nationwide Registry Analysis of Sociodemographic and Clinical Profiles for Glycaemic Control and Complications
by: Chao Deng, et al.
Published: (2026)

GLP‐1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk
by: Hiba Jebeile, et al.
Published: (2025)

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP ‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
by: Yazan Alhamdan, et al.
Published: (2026)

RETRACTION : Effects of GLP ‐1 Receptor Agonists on Cognitive Function in Patients With Type 2 Diabetes: A Systematic Review and Meta‐Analysis Based on Randomized Controlled Trials
Published: (2026)

Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes
by: Zhimin Xu, et al.
Published: (2024)

GLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
by: Giorgia Rutigliani, et al.
Published: (2026)

Chronic Glycaemic Control Modulates the Relationship Between GIP and Glucagon Secretion Following Oral and Enteral Nutrients in Type 2 Diabetes
by: Zhenxi Wang, et al.
Published: (2026)

Identifying Predictors of Early Treatment Intensification in Individuals With Type 2 Diabetes Treated With GLP ‐1 Receptor Agonists: A Machine Learning–Based Analysis of a Large Real World Cohort
by: Pierpaolo Falcetta, et al.
Published: (2026)

Interpreting Pregnancy Risk After GLP ‐1 Receptor Agonists Discontinuation
by: Roberta Scairati, et al.
Published: (2026)

Equivalent Acute Anti‐Inflammatory Effects of Exercise in Type 2 Diabetes Versus Healthy Adults: A Randomised Crossover Study
by: Yu‐Min Huang, et al.
Published: (2026)

Micronutrient and Nutritional Deficiencies Associated With GLP ‐1 Receptor Agonist Therapy: A Narrative Review
by: Jorge Urbina, et al.
Published: (2026)

Beyond GLP ‐1 Monotherapy: Novel Multi‐Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes
by: Mikhail Khachaturov, et al.
Published: (2026)

Comparative Analysis of Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes Mellitus: Insights From a Saudi Arabian Cohort
by: Sadiq A. Alali, et al.
Published: (2025)

Low‐Dose Glucagon After Fasted Morning Exercise in People With Type 1 Diabetes—A Randomised Crossover Comparison of Low and High Carbohydrate Diets
by: Signe Schmidt, et al.
Published: (2026)

Association of GLP ‐1 Receptor Agonists With Hepatic Decompensation in the All of Us Research Program
by: Inyoung Hwang, et al.
Published: (2026)

Weight Loss Outcomes Between GLP ‐1 Receptor Agonists and Bariatric Surgery in Adults With Obesity: A Systematic Review, Meta‐Analysis and Meta‐Regression
by: Muhammad Tahir, et al.
Published: (2026)

Weight Loss With GLP ‐1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta‐Analysis
by: Michael Lim, et al.
Published: (2026)